Dr. Marla Shapiro spoke at the recent CNS Day at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO Paris 2019) on patient empowerment. Watch this short video where Dr. […]
There are many questions for those taking osteoporosis medications and treatments including why they are being prescribed, concerns over side effects and the importance of sticking to a medication schedule. […]
Dr. Mohit Bhandari, a member of the SAC Executive committee, a Professor in the Department of Surgery at McMaster University and a leader in the field of orthopedic surgery has […]
We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
There has been recent media coverage concerning a rare atypical femoral fracture that may be a side effect of denosumab (Prolia), an osteoporosis medication manufactured by Amgen. Osteoporosis Canada’s Scientific […]
Osteoporosis Canada’s overall position statement in response to this study: This study did not specifically address the vitamin D requirements of individuals with osteoporosis, those with risk factors for osteoporotic […]
Media OC Replay Osteoporosis Canada’s REPLAY features some of our most popular online content on bone health and managing osteoporosis. VIEW Unbreakable – The OC Podcast UNBREAKABLE – The OC […]
